BR112012005511A2 - 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl - Google Patents

5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl

Info

Publication number
BR112012005511A2
BR112012005511A2 BR112012005511A BR112012005511A BR112012005511A2 BR 112012005511 A2 BR112012005511 A2 BR 112012005511A2 BR 112012005511 A BR112012005511 A BR 112012005511A BR 112012005511 A BR112012005511 A BR 112012005511A BR 112012005511 A2 BR112012005511 A2 BR 112012005511A2
Authority
BR
Brazil
Prior art keywords
nicotinamide
trifluoro
dichloro
ethoxy
cyclohexyl
Prior art date
Application number
BR112012005511A
Other languages
English (en)
Other versions
BR112012005511B1 (pt
BR112012005511B8 (pt
Inventor
Matthew Wright
Stephan Roever
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012005511A2 publication Critical patent/BR112012005511A2/pt
Publication of BR112012005511B1 publication Critical patent/BR112012005511B1/pt
Publication of BR112012005511B8 publication Critical patent/BR112012005511B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012005511A 2009-09-11 2010-09-08 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6-(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl BR112012005511B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
EP09170097.1 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (3)

Publication Number Publication Date
BR112012005511A2 true BR112012005511A2 (pt) 2016-04-19
BR112012005511B1 BR112012005511B1 (pt) 2021-03-02
BR112012005511B8 BR112012005511B8 (pt) 2021-05-25

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005511A BR112012005511B8 (pt) 2009-09-11 2010-09-08 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6-(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl

Country Status (35)

Country Link
US (1) US8227491B2 (pt)
EP (1) EP2475645B1 (pt)
JP (1) JP5604520B2 (pt)
KR (1) KR101382871B1 (pt)
CN (1) CN102639506B (pt)
AR (2) AR078352A1 (pt)
AU (1) AU2010294277B2 (pt)
BR (1) BR112012005511B8 (pt)
CA (1) CA2771493C (pt)
CL (1) CL2012000611A1 (pt)
CO (1) CO6491033A2 (pt)
CR (1) CR20120089A (pt)
CY (1) CY1114377T1 (pt)
DK (1) DK2475645T3 (pt)
EC (1) ECSP12011723A (pt)
ES (1) ES2423821T3 (pt)
HK (1) HK1172021A1 (pt)
HR (1) HRP20130869T1 (pt)
IL (1) IL217920A (pt)
IN (1) IN2012DN00763A (pt)
MA (1) MA33563B1 (pt)
MX (1) MX2012002254A (pt)
MY (1) MY161103A (pt)
NZ (1) NZ597514A (pt)
PE (1) PE20120863A1 (pt)
PL (1) PL2475645T3 (pt)
PT (1) PT2475645E (pt)
RS (1) RS52987B (pt)
RU (1) RU2541475C2 (pt)
SG (1) SG179035A1 (pt)
SI (1) SI2475645T1 (pt)
TW (1) TWI412363B (pt)
UA (1) UA107088C2 (pt)
WO (1) WO2011029827A1 (pt)
ZA (1) ZA201201599B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CA2602787C (en) * 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
CA2664119A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
ECSP12011723A (es) 2012-04-30
EP2475645A1 (en) 2012-07-18
BR112012005511B1 (pt) 2021-03-02
AR078352A1 (es) 2011-11-02
UA107088C2 (xx) 2014-11-25
CY1114377T1 (el) 2016-08-31
RU2541475C2 (ru) 2015-02-20
CR20120089A (es) 2012-03-22
HK1172021A1 (en) 2013-04-12
IL217920A (en) 2015-11-30
PL2475645T3 (pl) 2013-12-31
KR101382871B1 (ko) 2014-04-08
RU2012113924A (ru) 2013-10-20
PT2475645E (pt) 2013-08-05
HRP20130869T1 (hr) 2013-10-25
WO2011029827A1 (en) 2011-03-17
RS52987B (en) 2014-02-28
CA2771493A1 (en) 2011-03-17
CA2771493C (en) 2017-08-29
MX2012002254A (es) 2012-03-16
AU2010294277B2 (en) 2015-07-09
SI2475645T1 (sl) 2013-10-30
TWI412363B (zh) 2013-10-21
DK2475645T3 (da) 2013-07-22
BR112012005511B8 (pt) 2021-05-25
MA33563B1 (fr) 2012-09-01
TW201114427A (en) 2011-05-01
ZA201201599B (en) 2012-11-28
US20110065759A1 (en) 2011-03-17
CN102639506A (zh) 2012-08-15
CN102639506B (zh) 2014-09-03
AR114032A2 (es) 2020-07-15
US8227491B2 (en) 2012-07-24
IL217920A0 (en) 2012-03-29
IN2012DN00763A (pt) 2015-06-26
JP2013504534A (ja) 2013-02-07
NZ597514A (en) 2013-10-25
CO6491033A2 (es) 2012-07-31
ES2423821T3 (es) 2013-09-24
AU2010294277A1 (en) 2012-02-09
JP5604520B2 (ja) 2014-10-08
CL2012000611A1 (es) 2012-09-07
EP2475645B1 (en) 2013-07-03
SG179035A1 (en) 2012-04-27
KR20120048040A (ko) 2012-05-14
PE20120863A1 (es) 2012-07-23
MY161103A (en) 2017-04-14

Similar Documents

Publication Publication Date Title
BR112012005511A2 (pt) 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl
LTC2459208I2 (lt) Terapiniai agentai, skirti prieskydinės liaukos hormono lygio sumažinimui
BRPI0907641A2 (pt) Piridinas fundidas ativas como inibidores de c-met
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
BRPI1010881A2 (pt) derivados de triazina e suas aplicações terapêuticas.
EP2360155A4 (en) 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
BRPI1010882A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
BRPI1008948A2 (pt) nicotinamida substituída como moduladores kcnq2/3.
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
BRPI1015967A2 (pt) "unidade de dobradiça, e, peça de mobília."
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0809971A2 (pt) Derivados de piridina e pirimidina como antagosnistas de mglur2
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BRPI1014583A2 (pt) sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo.
BR112012000303A2 (pt) antagonistas da via hedgehog e aplicações terapêuticas dos mesmos
BRPI0924140A2 (pt) pinça de microcirurgia, em particular pinça de capsulorrexe por microincisão
IL215483A0 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
ZA200805756B (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivative
BRPI1008019A2 (pt) derivados de 6-(6-substituido-triazolo piridazina-sufanil) 5-flúor-benzo-tiazóis e 5-flúor-benzimidazóis: preparo, aplicação como medicamentos e utilização como inibidores de met
EP2111400A4 (en) Pyridine compounds and their use as P2Y12 antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF